<DOC>
	<DOCNO>NCT02908191</DOCNO>
	<brief_summary>This two-part , Phase 1 protocol first clinical study ABI-H0731 . Part I Phase 1a dose-ranging assessment ABI-H0731 healthy adult volunteer . If dose-related safety , tolerability pharmacokinetics ( PK ) ABI-H0731 human volunteer deem satisfactory , study advance Part II , Phase 1b dose-ranging assessment ABI-H0731 non-cirrhotic , CHB patient .</brief_summary>
	<brief_title>A Study Healthy Volunteers Patients With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Healthy volunteer : 1 . Male female 18 65 year old BMI 1832kg/m2 2 . Must good health health condition could interfere absorption , distribution elimination study drug , clinical laboratory assessment study CHB patient : 1 . Male female 18 65 year age , BMI 1835kg/m2 2 . Must chronic hepatitis B history clinical decompensation 3 . Must treat hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>